United Kingdom · Question · Written question
UIN 37488
Myasthenia Gravis: Medical Treatments
Original
Introduced
11 March 2025
Last action
18 March 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
18 March 2025
Summary
To ask the Secretary of State for Health and Social Care, what his planned timetable is for when patients with Myasthenia Gravis will have access to recently licenced products.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
11 March 2025
Written question
To ask the Secretary of State for Health and Social Care, what his planned timetable is for when patients with Myasthenia Gravis will have access to recently licenced products.
Source: Commons
18 March 2025
Answer
On 7 March 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the medicine rozanolixizumab, marketed as Rystiggo, to treat adults with generalised myasthenia gravis.The National Institute for Health and Care Excellence (NICE) ev...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-03-11/37488
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1783465
- uk · wq-1783465 · source updated 18 March 2025